Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Oct 3;29(10):821-823.
doi: 10.1093/oncolo/oyae230.

Liquid biopsy in renal cell carcinoma

Marc Machaalani  1 , Marc Eid  1 , Karl Semaan  1 , Razane El Hajj Chehade  1 , Rashad Nawfal  1 , Sylvan C Baca  1   2 , Toni K Choueiri  1   2
Affiliations
Comment

Liquid biopsy in renal cell carcinoma

Marc Machaalani et al. Oncologist. .

Abstract

This commentary focuses on the article by Correa et al on the association of circulating tumor DNA with patient prognosis in renal cell carcinoma.

PubMed Disclaimer

Conflict of interest statement

Sylvan Baca is a co-founder and shareholder of Precede Biosciences. Toni K. Choueiri reports institutional and/or personal, paid and/or unpaid support for research, advisory boards, consultancy, and/or honoraria past 5 years, ongoing or not, from: Alkermes, Arcus Bio, AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers-Squibb, Calithera, Circle Pharma, Deciphera Pharmaceuticals, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Gilead, HiberCell, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Neomorph, Nuscan/PrecedeBio, Novartis, Oncohost, Pfizer, Roche, Sanofi/Aventis, Scholar Rock, Surface Oncology, Takeda, Tempest, Up-To-Date, CME events (Peerview, OncLive, MJH, CCO and others), outside the submitted work. Institutional patents filed on molecular alterations and immunotherapy response/toxicity, and ctDNA. Equity: Tempest, Pionyr, Osel, Precede Bio, CureResponse, InnDura Therapeutics, Primium Committees: NCCN, GU Steering Committee, ASCO (BOD 6-2024-, ESMO, ACCRU, KidneyCan). Medical writing and editorial assistance support may have been funded by Communications companies in part. No speaker’s bureau. Mentored several non-US citizens on research projects with potential funding (in part) from non-US sources/Foreign Components. The institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or/and royalties potentially involved in research around the subject matter. T. K. Choueiri is supported in part by the Dana-Farber/Harvard Cancer Center Kidney SPORE (2P50CA101942-16) and Program 5P30CA006516-56, the Kohlberg Chair at Harvard Medical School and the Trust Family, Michael Brigham, Pan Mass Challenge, Hinda and Arthur Marcus Fund and Loker Pinard Funds for Kidney Cancer Research at DFCI. The other authors indicated no financial relationships.

Comment on

References

    1. Alix-Panabières C, Pantel K.. Liquid biopsy: from discovery to clinical application. Cancer Discov. 2021;11(4):858-873. 10.1158/2159-8290.CD-20-1311 - DOI - PubMed
    1. Yamamoto Y, Uemura M, Fujita M, et al.. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma. Cancer Sci. 2019;110(2):617-628. 10.1111/cas.13906 - DOI - PMC - PubMed
    1. Lin YL, Wang YP, Li HZ, Zhang X.. Aberrant promoter methylation of PCDH17 (Protocadherin 17) in serum and its clinical significance in renal cell carcinoma. Med Sci Monit. 2017;23:3318-3323. 10.12659/msm.902077 - DOI - PMC - PubMed
    1. Correa AF, Kalashnikova E, Wu HT, et al.. Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinoma. Oncologist. 2024:oyae180. 10.1093/oncolo/oyae180 - DOI - PMC - PubMed
    1. Smith CG, Moser T, Mouliere F, et al.. Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors. Genome Med. 2020;12(1):23. 10.1186/s13073-020-00723-8 - DOI - PMC - PubMed